Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Haiguang Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Mar 30
Viva Biotech Holdings, Annual General Meeting, Jun 26, 2026 Viva Biotech Holdings, Annual General Meeting, Jun 26, 2026. Announcement • Mar 19
Viva Biotech Optimizes Proteina-Complexa Model And Advances Lab-In-The-Loop Workflow With NVIDIA Technology Viva Biotech optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of novel therapeutics with AI-driven designs with NVIDIA technology. The collaboration highlights Viva Biotech's Lab-in-the-Loop workflow, combining de novo computational design with high throughput protein production and biophysical evaluation to design ActRIIA binders. This integrated approach demonstrates how in silico predictions with real-world experimental validations can expedite drug discovery, showcasing the effectiveness of NVIDIA BioNeMo and Viva Biotech's AI-driven integrated drug discovery platform in optimizing drug candidates. As part of this effort, Viva Biotech leverages its AI technique for sequence selection and provide valuable feedback to improve the original Proteina-Complexa model. This iteration led to more efficient and targeted mini-binder designs. Guided by AI-driven insights, the company successfully explored previously uncharted chemical space and significantly enhanced design specificity, achieving these advances at a fraction of the cost and time compared with conventional drug candidate nomination processes. Announcement • Mar 18
Viva Biotech Holdings to Report Fiscal Year 2025 Results on Mar 30, 2026 Viva Biotech Holdings announced that they will report fiscal year 2025 results on Mar 30, 2026 Announcement • Feb 16
Viva Biotech Holdings Announces Resignation of Wang Stephen Hui as Non-Executive Director, Effective February 16, 2026 Viva Biotech Holdings announced that Mr. Wang Stephen Hui has tendered his resignation from the office of a non-executive Director on February 16, 2026 with immediate effect. Mr. Wang resigned from his position in order to devote more time to pursue his other personal and business engagements. As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang. Announcement • Aug 18
Viva Biotech Holdings to Report First Half, 2025 Results on Aug 28, 2025 Viva Biotech Holdings announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • Mar 17
Viva Biotech Holdings to Report Fiscal Year 2024 Results on Mar 27, 2025 Viva Biotech Holdings announced that they will report fiscal year 2024 results on Mar 27, 2025 Reported Earnings • Sep 30
First half 2024 earnings released: EPS: CN¥0.055 (vs CN¥0.001 in 1H 2023) First half 2024 results: EPS: CN¥0.055 (up from CN¥0.001 in 1H 2023). Revenue: CN¥981.8m (down 14% from 1H 2023). Net income: CN¥116.8m (up CN¥115.8m from 1H 2023). Profit margin: 12% (up from 0.1% in 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 17 percentage points per year, which is a significant difference in performance. Announcement • Sep 27
Viva Biotech Holdings Announces Chief Financial Officer Changes Viva Biotech Holdings announced with effect from September 27, 2024, Mr. WANG Zheren (‘Mr. Wang’) has tendered his resignation from the role of Co-Chief Financial Officer of the Group with effect from the date of this announcement. Mr. Wang will remain with the Group and continue to serve as the Chief Financial Officer of Viva Shanghai, and will be primarily responsible for leading Viva Shanghai's financial management and strategic development, as well as serving as the secretary to the board of Viva Shanghai. The change in roles and responsibilities will enable Mr. Wang to focus more of his attention on leading the financial management and strategic development of Viva Shanghai. Upon the proposed change in roles, Mr. XIONG Wei, the other Co-Chief Financial Officer of the Group, will assume the role as the Chief Financial Officer of the Group, and will primarily responsible for leading the Group's financial management and capital market related affairs. The Company confirms that there are no other matters required to be brought to the attention of the shareholders of the Company in relation to the change of roles of the Co-Chief Financial Officers. Announcement • Sep 05
Viva Biotech Holdings (SEHK:1873) commences an Equity Buyback Plan for 216,136,630 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2024. Viva Biotech Holdings (SEHK:1873) commences share repurchases on September 5, 2024, under the program mandated by the shareholders in the Annual General Meeting held on June 26, 2024. As per the mandate, the company is authorized to repurchase up to a maximum of 216,136,630 shares, representing 10% of the issued share capital. The purpose of the program is to enhance the net asset value per share and/or earnings per share. The repurchases will be funded entirely from the cash flow or working capital facilities available to the Company and funds legally available for the purpose in accordance with the Articles of Association, applicable laws of the Cayman Islands and the Listing Rules. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 26, 2024, the company had 2,161,366,305 shares in issue.
On August 29, 2024, the company announced a share repurchase program. Under the program, the company will repurchase HKD 100 million worth of shares. The repurchases will be funded from company's internal resources. The repurchased shares will be cancelled or hold them as
treasury shares. Announcement • Aug 20
Viva Biotech Holdings to Report First Half, 2024 Results on Aug 29, 2024 Viva Biotech Holdings announced that they will report first half, 2024 results on Aug 29, 2024 Reported Earnings • Apr 30
Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022) Full year 2023 results: CN¥0.06 loss per share (improved from CN¥0.28 loss in FY 2022). Revenue: CN¥2.16b (down 9.4% from FY 2022). Net loss: CN¥116.1m (loss narrowed 78% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Announcement • Mar 29
Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024 Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024. Reported Earnings • Mar 29
Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022) Full year 2023 results: CN¥0.06 loss per share (improved from CN¥0.28 loss in FY 2022). Revenue: CN¥2.16b (down 9.4% from FY 2022). Net loss: CN¥116.1m (loss narrowed 78% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings. Announcement • Mar 19
Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024 Viva Biotech Holdings announced that they will report fiscal year 2023 results on Mar 28, 2024 New Risk • Jan 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (12% increase in shares outstanding). Announcement • Jan 18
Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director Viva Biotech Holdings at its extraordinary general meeting held on January 18, 2024, the board announced that Mr. WANG Stephen Hui ("Mr. Wang") was appointed as a non-executive Director with effect from January 18, 2024. He will hold office for a term of three years. Announcement • Dec 02
Viva Biotech Holdings Announces Executive Changes The board of directors of Viva Biotech Holdings announced that Mr. REN Delin (Mr. Ren), an executive director of the company will begin serving as the general manager and chief executive officer of Viva Biotech (Shanghai) Ltd. and will cease to serve as the president of the company, effective December 1, 2023. Mr. Ren will continue to serve on the board of the company as an executive director and will remain as a member of Viva Shanghai's senior management team. He will serve as the general manager and chief executive officer of Viva Shanghai and will remain responsible for the overall management of the Group's contract research organization (CRO) and drug discovery functions. The other roles and responsibilities previously held by Mr. Ren as president of the company Will be assumed by Mr. MAO Chen Cheney, the chief executive officer of the group and chairman of the company. The change in executive responsibilities will enable Mr. Ren to focus more of his attention to leading the Group's CRO and drug discovery businesses. Announcement • Dec 01
Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer The board of directors of Viva Biotech Holdings announced that Mr. XIONG Wei (Mr. Xiong) has been appointed as the co-chief financial officer of the group with effect from December 1, 2023 and in such role, he will be reporting to Mr. Mao. Mr. Xiong will be responsible for jointing leading the Group's financial management and capital market related affairs along with Mr. WANG Zheren (Mr. Wang), the Group's current Chief Financial Officer. Mr. Xiong will be primarily focused on the financial management of the Group's contract design and manufacturing (CDMO) and commercialization services while Mr. Wang will be primarily focused on the financial management of the Group's CRO and drug discovery services. Mr. Xiong, aged 40, joined its Group in November 2020 as part of the Group's acquisition of Zhejiang Langhua Pharmaceutical Co. Ltd., he currently serves as the financial director of Langhua Pharmaceutical and is primarily responsible for its financial management. Mr. Xiong joined Langhua Pharmaceutical in September 2018. Prior to that, Mr. Xiong was employed by Donghaixiang Group Co. Ltd. from November 2011 to September 2018 where he last served as the executive vice general manager and financial director. He was employed by Zhejiang Yongtai Technology Co. Ltd. from May 2007 to November 2011 where he last served as the investment director and securities business representatives and by CITIC Securities where he last served as an industry analyst from July 2005 to November 2006. Mr. Xiong graduated from the Huazhong University of Science and Technology School of Economics with a degree in international economics and trade and from the Zhongnan University of Economics and Law with a degree in law in June 2005. He is qualified to serve as a board secretary for companies listed on the Shanghai Stock Exchange and Shenzhen Stock Exchange, and has been qualified as a senior economist since November 2023. New Risk • Nov 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 31
First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022) First half 2023 results: EPS: CN¥0.001 (up from CN¥0.048 loss in 1H 2022). Revenue: CN¥1.14b (up 3.0% from 1H 2022). Net income: CN¥1.01m (up CN¥92.2m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Announcement • Aug 18
Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023 Viva Biotech Holdings announced that they will report first half, 2023 results on Aug 29, 2023 Announcement • Jul 08
Viva Biotech Holdings announced that it has received HKD 470 million in funding On July 7, 2023, Viva Biotech Holdings, closed the transaction. New Risk • Jun 27
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Reported Earnings • Apr 02
Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021) Full year 2022 results: CN¥0.28 loss per share (down from CN¥0.15 profit in FY 2021). Revenue: CN¥2.38b (up 13% from FY 2021). Net loss: CN¥528.5m (down 284% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Haiguang Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Nov 15
Viva Biotech Holdings Announces Board Changes The board of directors of Viva Biotech Holdings announces the following changes of directors of the Company: Ms. SUN Yanyan ("Ms. SUN") has tendered her resignation from the office of a non-executive Director on November 14, 2022 with immediate effect. Ms. SUN resigned from her position in order to devote more time to pursue her other business engagements and has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company (the "Shareholder(s)") and The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The Board is delighted to announce that following Ms. SUN's resignation, the Board appointed Mr. WU Yuting ("Mr. WU") as a non-executive Director with effect from November 14, 2022. Mr. WU, aged 51, was previously an investment director and partner of Fenghe Fund Management Pte. Ltd. since May 2010. He was a general manager at Shanghai Zhifang Electronic Technology Co.,Ltd. from July 1997 to January 2006. He was also an engineer at Shanghai Changjiang Computer System Integration Company from September 1994 to July 1997. Mr. WU obtained his bachelor's degree in computer and application from the Shanghai Jiao Tong University in July 1994, and he further obtained his international master's degree in business administration from the Schulich School of Business of York University in June 2008. In addition, Mr. WU is the brother of Mr. John WU Jiong, a substantial Shareholder of the Company who is taken to be interested in Shares held by Fenghe Harvest Ltd, Wu and Sons Limited and Fenghe CanaryLimited, each being a corporation controlled by him. Reported Earnings • Aug 31
First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021) First half 2022 results: CN¥0.048 loss per share (down from CN¥0.044 profit in 1H 2021). Revenue: CN¥1.11b (up 8.0% from 1H 2021). Net loss: CN¥91.2m (down 207% from profit in 1H 2021). Over the next year, revenue is forecast to grow 46%, compared to a 14% growth forecast for the Life Sciences industry in Germany. Announcement • Aug 18
Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022 Viva Biotech Holdings announced that they will report first half, 2022 results on Aug 29, 2022 Announcement • Aug 13
Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022 Viva Biotech Holdings provided earnings guidance for the six months ended June 30, 2022. For the period, revenue of the Group is expected to increase by over 5% as compared with the corresponding period of last year, of which revenue from the CRO business is expected to increase by over 25%, and revenue from the CDMO business is expected to remain relatively stable; and the Group is expected to record a net loss of not more than RMB 100 million for the Period as compared to the net profit of RMB 95.8 million reported for the six months ended June 30, 2021. Based on the information currently available, the Board considers that the net loss is mainly attributable to (i) the resurgence of COVID-19 in mainland China limiting delivery of the Group's products and services to customers during the Period; (ii) market fluctuation resulting in negative fair value changes in the Group's equity interest in incubation portfolio companies; and (iii) fluctuation of foreign exchange rates during the Period resulting in foreign exchange losses for the Group. Reported Earnings • May 01
Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.25 loss in FY 2020) Full year 2021 results: EPS: CN¥0.15 (up from CN¥0.25 loss in FY 2020). Revenue: CN¥2.10b (up 202% from FY 2020). Net income: CN¥287.5m (up CN¥674.4m from FY 2020). Profit margin: 14% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 30%, compared to a 12% growth forecast for the pharmaceuticals industry in Germany. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Haiguang Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.25 loss in FY 2020) Full year 2021 results: EPS: CN¥0.15 (up from CN¥0.25 loss in FY 2020). Revenue: CN¥2.10b (up 202% from FY 2020). Net income: CN¥287.5m (up CN¥674.4m from FY 2020). Profit margin: 14% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 49%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany. Announcement • Mar 07
Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021 Viva Biotech Holdings provided unaudited consolidated earnings guidance for the year ended December 31, 2021. For the year, the company expects that the revenue for the Year will increase by no less than RMB 1,300 million or over 180% to approximately RMB 2,000 million as compared to that for the year ended December 31, 2020. The Group expects to record a net profit of no less than RMB 300 million for the Year as compared with a net loss of RMB 378.9 million for the year ended December 31, 2020. The Group expects to record a net profit attributable to the equity shareholders of the Company of no less than RMB 280 million for the Year as compared with a net loss attributable to the equity shareholders of the Company of RMB 386.9 million for the year ended December 31, 2020. Recent Insider Transactions • Oct 01
Executive VP & Executive Director recently bought €125k worth of stock On the 29th of September, Ying Wu bought around 200k shares on-market at roughly €0.62 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €62m more in shares than they bought in the last 12 months. Reported Earnings • Sep 02
First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CN¥1.03b (up 420% from 1H 2020). Net income: CN¥85.0m (up CN¥615.3m from 1H 2020). Profit margin: 8.3% (up from net loss in 1H 2020). Recent Insider Transactions • Jul 17
Insider recently sold €38m worth of stock On the 14th of July, Fengmao Hua sold around 40m shares on-market at roughly €0.94 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €62m more than they bought in the last 12 months. Executive Departure • Jul 13
Executive Director Fengmao Hua has left the company On the 30th of June, Fengmao Hua's tenure as Executive Director ended after less than a year in the role. As of March 2021, Fengmao still personally held 130.10m shares (€94m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.00 years. Upcoming Dividend • Jun 09
Upcoming dividend of HK$0.01 per share Eligible shareholders must have bought the stock before 16 June 2021. Payment date: 09 July 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.5%). Announcement • Apr 29
Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021 The Board of Viva Biotech Holdings has resolved to recommend the declaration and payment of a final dividend of HKD 0.01 per share for the year ended December 31, 2020. Subject to the approval of the shareholders at the forthcoming annual general meeting of the company, the proposed final dividend is expected to be paid on or about July 9, 2021. Recent Insider Transactions • Apr 24
Executive Director & CFO recently sold €27m worth of stock On the 19th of April, Fengmao Hua sold around 38m shares on-market at roughly €0.72 per share. This was the largest sale by an insider in the last 3 months. Fengmao has been a seller over the last 12 months, reducing personal holdings by €26m. Reported Earnings • Mar 31
Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019) The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2020 results: Revenue: CN¥697.0m (up 116% from FY 2019). Net loss: CN¥386.9m (down 246% from profit in FY 2019). Announcement • Mar 21
Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020 Viva Biotech Holdings provided earnings guidance for the year ended December 31, 2020. For the year, the company expected net loss no higher than RMB 400 million, as compared to the net profit of approximately RMB 266 million for the year ended December 31, 2019. Announcement • Mar 19
Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021 Viva Biotech Holdings announced that they will report fiscal year 2020 results on Mar 30, 2021 Announcement • Mar 17
Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020 Viva Biotech Holdings announced based on the preliminary assessment of the latest unaudited management accounts of the Group and information currently available, for the year ended December 31, 2020 (the "Year") the Group is expected to record a significant amount of net loss during the Year as compared to the net profit reported for the year ended December 31, 2019. Based on the information currently available, the Board considers that the significant net loss is mainly attributable to an extraordinary loss of approximately RMB600 million in relation to the Convertible Bonds issued in compliance with the International Financial Reporting Standards ("IFRS"). Is New 90 Day High Low • Feb 25
New 90-day low: €0.72 The company is down 5.0% from its price of €0.76 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.17 per share. Is New 90 Day High Low • Jan 20
New 90-day high: €0.95 The company is up 16% from its price of €0.82 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.16 per share. Is New 90 Day High Low • Nov 25
New 90-day low: €0.73 The company is down 25% from its price of €0.97 on 27 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.095 per share. Announcement • Nov 05
Viva Biotech Holdings Announces Resignation of MAO Jun as Non-Executive Director The board of directors of Viva Biotech Holdings announced that Ms. MAO Jun has tendered her resignation from the office of a non-executive Director of the Company on November 3, 2020 with immediate effect. Recent Insider Transactions • Oct 17
Executive Director & CFO recently bought €771k worth of stock On the 15th of October, Fengmao Hua bought around 850k shares on-market at roughly €0.91 per share. This was the largest purchase by an insider in the last 3 months. This was Fengmao's only on-market trade for the last 12 months. Is New 90 Day High Low • Oct 16
New 90-day low: €0.89 The company is down 6.0% from its price of €0.94 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.15 per share. Reported Earnings • Sep 29
First half earnings released Over the last 12 months the company has reported total losses of CN¥310.9m, with earnings decreasing by CN¥398.1m from the prior year. Total revenue was CN¥378.3m over the last 12 months, up 37% from the prior year. Announcement • Aug 22
Viva Biotech Holdings to Report First Half, 2020 Results on Aug 31, 2020 Viva Biotech Holdings announced that they will report first half, 2020 results on Aug 31, 2020 Announcement • Jul 17
Viva Biotech Holdings has completed a Follow-on Equity Offering in the amount of HKD 1.0595 billion. Viva Biotech Holdings has completed a Follow-on Equity Offering in the amount of HKD 1.0595 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 130,000,000
Price\Range: HKD 8.15
Discount Per Security: HKD 0.07
Transaction Features: Subsequent Direct Listing 
